We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




IFN‐γ Release Assay Helps Diagnose Hemophagocytic Lymphohistiocytosis

By LabMedica International staff writers
Posted on 14 Aug 2020
Hemophagocytic lymphohistiocytosis (HLH), either primary (pHLH, or Familiar, FHL) or secondary is a life‐threatening hyper‐inflammatory syndrome, characterized by massive and uncontrolled activation of macrophages and T cells, causing fever, cytopenia and liver dysfunction with coagulopathy.

The rarity of the HLH disease, along with its pleomorphic clinical presentation that mimics a number of different conditions (from severe infections to malignancies), makes the diagnosis challenging. More...
Hemophagocytosis on bone morrow biopsy is the only histomorphological criterion, but, in itself, it is neither specific nor sensitive.

Hematologists at the Bambino Gesù Children's Hospital (Rome, Italy) diagnosed and treated 13 children with pHLH at the hospital from August 2014 to April 2020. During the diagnostic evaluation, all patients were tested for tuberculosis (TB) exposure through QuantiFERON‐TB Gold (QFT‐G, Qiagen, Hilden, Germany). The QuantiFERON test is an IFN‐γ release assay (IGRA), which measures IFN‐γ release in response to tuberculosis (TB)‐specific antigens. After centrifugation, plasma was harvested and enzyme‐linked immunosorbent assay (ELISA) tests were run.

The scientists reported that results obtained from the HLH group (all tests were reported as ‘Indeterminate’ because of high levels of IFN‐γ in the NIL Tube) were compared with three other groups of pediatric patients (matched for gender) with an available QFT‐G. These groups were: 13 children hospitalized for acute leukemia (AL) at time of diagnosis, 13 because of sepsis and 13 healthy controls (HC). The median (range) IFN‐γ levels at diagnosis/before starting treatment in the HLH group was 2.49 IU/mL (0.12–15.11) , significantly higher than those found in the AL, sepsis and HC groups, in which the median (range) value was 0.04 IU/mL (0.02–0.11) 0.07 (IU/mL 0.03–0.15) and 0.036 IU/mL (0.015–0.077) , respectively. A cut‐off value of 0.12 IU/mL had a sensitivity of 100% and a specificity of 97.3%.

The authors concluded that QFT‐G Plus, a diffuse and standardized blood test, in association with HLH‐04 criteria could support clinicians in determining a diagnosis of pHLH with high sensitivity and specificity. Although other interferonopathies, genetic or acquired, such as systemic lupus erythematosus and juvenile dermatomyositis, could impair the specificity of the analysis, this simple diagnostic test could really support pediatricians in peripheral hospitals. The study was published on July 26, 2020 in the British Journal of Haematology.

Related Links:

Bambino Gesù Children's Hospital
Qiagen

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: The Fast PCR System delivers sample‑to‑answer results for key pathogens in under 10 minutes (Photo courtesy of Autonomous Medical Devices Incorporated)

Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes

Respiratory syncytial virus, influenza, and SARS-CoV-2 remain major respiratory pathogens in ambulatory care. RSV is a particular priority because it can cause significant disease in infants, older adults,... Read more

Microbiology

view channel
Image: Burkholderia pseudomallei is a soil-dwelling bacterium that causes melioidosis, a severe and potentially fatal infection that remains difficult to diagnose (Image Credit: Gavin Koh/Wikimedia Commons, CC BY-SA 4.0)

Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread

Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.